JYSELECA - A JAK1 preferential inhibitor for moderate to severe RA1

Sustained efficacy2-8

‘JYSELECA Journeys’ by Film JYSELECA

Episode 2 - Showing Strength

In Phase 3 trials, JYSELECA demonstrated:

Rapid and lasting efficacy from Week 2 to Week 52, with or without MTX2-4

DAS28-CRP <2.6 remission in MTX-IR and biologic-IR patients2,3

Successful inhibition of radiographic progression2,4,7

Discover Strength of Balance

ACR Data

DAS28-CRP Remission

Radiographic Progression

vs. Adalimumab

JYSELECA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).1 JYSELECA may be used as monotherapy or in combination with methotrexate (MTX).1

References: 1. JYSELECA SPC. Available at: www.medicines.org.uk / www.medicines.ie.. Last accessed: November 2022. 2. Combe B, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219214. 3. Genovese MC, et al. JAMA 2019;322 (4):315–325. 4. Westhovens R, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219213. 5. Combe B, et al. Arthritis Rheumatol 2021;73(suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-filgotinib-treatment-in-an-ongoing-long-term-extension-trial-of-ra-patients-with-inadequate-response-to-mtx-initially-treated-with-filgotinib-or-adalimumab-during-th/. Last accessed: November 2022. 6. Buch MH, et al. Arthritis Rheumatol 2021;73 (suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-ongoing-filgotinib-ra-long-term-extension-trial-of-biologic-dmard-inadequate-responders-initially-on-filgotinib-or-placebo-in-a-phase-3-trial/. Last accessed: November 2022. 7. Data on file - Gilead Sciences Ltd - INF-UK-20-04. 8. Data on file - Gilead Sciences Ltd - INF-UK-20-06. 9. Data on file - Gilead Sciences Ltd - INF-UK-20-11.

UK-RA-JY-202203-00018  | Date of preparation December 2022